Drug approval: Olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer

被引：2
作者：
Sabouret, Annabelle [1 ]
Beuzeboc, Philippe [2 ]
机构：
[1] Gustave Roussy, Serv Herault, 114 Rue Edouard Vaillant, F-94805 Villejuif, France
[2] Hop Foch, Serv Oncol & Soins Support, 40 Rue Worth, F-92151 Suresnes, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 04期
关键词：
Prostate cancer; Targeted therapies; PARP inhibitors; BRCA; Metastases;
D O I：
10.1016/j.bulcan.2023.01.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339 / 341
页数：3
相关论文
共 4 条
  • [1] Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design
    Agarwal, Neeraj
    Azad, Arun
    Shore, Neal D.
    Carles, Joan
    Fay, Andre P.
    Dunshee, Curtis
    Karsh, Lawrence Ivan
    Paccagnella, Maria Luisa
    Di Santo, Nicola
    Elmeliegy, Mohamed
    Lin, Xun
    Czibere, Akos
    Fizazi, Karim
    [J]. FUTURE ONCOLOGY, 2022, 18 (04) : 425 - 436
  • [2] Clarke Noel W, 2022, NEJM Evid, V1, pEVIDoa2200043, DOI 10.1056/EVIDoa2200043
  • [3] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2091 - 2102
  • [4] Homologous recombination deficiency and PARP inhibitors in therapeutics
    Salaun, Helene
    Saint-Ghislain, Mathilde
    Bellesoeur, Audrey
    Beuzeboc, Philippe
    Neuzillet, Cindy
    Dieras, Veronique
    Stern, Marc Henri
    Rodrigues, Manuel
    [J]. BULLETIN DU CANCER, 2022, 109 (01) : 76 - 82
1